MedTrace Logo

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

NCT06295770 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

Conditions

  • Fibrillary Glomerulonephritis

Interventions

DRUG

Obinutuzumab

Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.

Sponsors & Collaborators

Principal Investigators

  • Ladan Zand · Mayo Clinic

  • Fernando Fervenza, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06295770 on ClinicalTrials.gov